Avoid common mistakes on your manuscript.
Correction to: Adv Ther https://doi.org/10.1007/s12325-019-01052-y
In the original publication the colors of Fig. 2 have been switched. The corrected Fig. 2 is given below
Time to first major adverse cardiac event–plus (a) and time to first bleeding event (b)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Glassberg, M.K., Nathan, S.D., Lin, CY. et al. Correction to: Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. Adv Ther 36, 2927–2929 (2019). https://doi.org/10.1007/s12325-019-01082-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-019-01082-6